Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung CancerSolange Peters, Tony Mok, D. Ross Camidge et al.|New England Journal of Medicine|2017Cited by 2.4k
Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung CancerFred R. Hirsch, Brian R. Holloway, Marileila Varella‐Garcia et al.|Journal of Clinical Oncology|2006Cited by 702
Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung CancerLecia V. Sequist, D. Ross Camidge, Geoffrey R. Oxnard et al.|New England Journal of Medicine|2015Cited by 664
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung CancerChristian Rolfo, David R. Gandara, Philip C. Mack et al.|Journal of Thoracic Oncology|2021Cited by 642
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trialsAlexander Drilon, Robert C. Doebele, Salvatore Siena et al.|The Lancet Oncology|2019Cited by 537